CHINA
China | Data exclusivity comes into effect
Protection of Drug Trial Data on 15 May 2026 with immediate effect, i.e. simultaneously with the Implementing Regulations of the Drug Administration Law (2026 Revisions). The enforcement of...
Protection of Drug Trial Data on 15 May 2026 with immediate effect, i.e. simultaneously with the Implementing Regulations...
Read More
GREATER CHINA
China | Punitive damages in intellectual property civil cases
Supreme People Court (SPC) 2026 Judicial Interpretation. The 2026 SPC Interpretation further refines and supplements the rules set out in the 2021 version and addresses practical issues arising in judicial practice over recent years, including determining of...
Supreme People Court (SPC) 2026 Judicial Interpretation. The 2026 SPC Interpretation further refines and supplements the rules set out in the 2021 version and addresses...
Read More
AUSTRALASIA
Extending Protection for Pharmaceuticals | Requirements in Australia, China and Singapore
Our teams across the Asia Pacific explore how pharmaceutical innovators can extend protection for their therapeutic products through patent term extensions (PTEs) and data exclusivity in Australia, China, and Singapore.  A comparison table is provided below which summarises key requirements and timing considerations for...
Our teams across the Asia Pacific explore how pharmaceutical innovators can extend protection for their therapeutic products through patent term extensions (PTEs) and data...
Read More
CHINA
Market Exclusivity and Data Exclusivity included in Drug Administration Law revisions
Marking a milestone in China’s drug regulatory landscape, the 2026 Revisions of China’s Drug Administration Law introduce data exclusivity and market exclusivity into the regulatory framework, establishing a multi‑dimensional...
Marking a milestone in China’s drug regulatory landscape, the 2026 Revisions of China’s Drug Administration Law introduce data exclusivity...
Read More
GREATER CHINA
China | Amendments to Patent Examination Guidelines finalised
After six months of drafting and revisions, the China National Intellectual Property Administration (CNIPA) issued the finalised version of the Guidelines for Patent Examination on 13 November 2025. These revisions will...
After six months of drafting and revisions, the China National Intellectual Property Administration (CNIPA) issued the finalised version of...
Read More
GREATER CHINA
China | Establishing Inventive Step in Swiss-Type Use Claims – A Case Study on Disease Subtypes and Known APIs
As pharmaceutical innovation increasingly targets specific disease subtypes and personalised therapies, patent protection strategies must evolve accordingly—especially in jurisdictions like China, where method of treatment claims are not patentable. This...
As pharmaceutical innovation increasingly targets specific disease subtypes and personalised therapies, patent protection strategies must evolve accordingly—especially in jurisdictions...
Read More
GREATER CHINA
China | Patent examination shift for siRNA drugs in China
With the rapid expansion of siRNA research and application worldwide, the number of patent applications has also surged. An analysis of prosecution history of various siRNA patent applications in...
With the rapid expansion of siRNA research and application worldwide, the number of patent applications has also surged. An...
Read More
GREATER CHINA
Case study: A successful example of post-filing data to address the support issue under China patent practice
China previously applied stricter criteria for post-filing supplementary data during the examination of patent application, compared to other major patent systems. However, with the recent signing of an Economic...
China previously applied stricter criteria for post-filing supplementary data during the examination of patent application, compared to other major...
Read More

Find Your Expert

Experts

Contact Us

Enquiries

Receive Insights

Subscribe